吲达帕胺联合缬沙坦改善高血压合并糖尿病生化指标的应用

Application of indapamide combined with valsartan in improving biochemical indexes of hypertension complicated with diabetes

目的:分析吲达帕胺联合缬沙坦对高血压合并糖尿病患者血压及肾功能指标的改善作用。方法:纳入确诊患者78例,2020年7月至2022年6月行回顾性研究,根据用药方式分组,2020年7月至2021年6月为对照组(n=39)使用缬沙坦,2021年7月至2022年6月为观察组,例数均等,联合吲达帕胺,对比两组临床疗效、用药前后血压、胰岛素抵抗程度和肾功能。结果:观察组总有效率更高,两组比较有统计学意义(P<0.05);两组用药前血压、胰岛素抵抗程度和肾功能比较无显著差异性(P>0.05);观察组经药物治疗后,舒张压、收缩压、胰岛素抵抗指数、血肌酐、尿素氮和尿微量白蛋白水平更低,胰岛素分泌指数和胰岛素敏感指数更高,两组比较有统计学意义(P<0.05)。结论:吲达帕胺联合缬沙坦治疗高血压合并糖尿病,可更好控制血压达标,降低胰岛素抵抗程度,对肾功能有改善作用,治疗效果明显提高。

Objective:To analyze the improvement effect of indapamide combined with valsartan on blood pressure and renal function in hypertensive patients with diabetes.Methods:A retrospective study was carried out in 78 patients with confirmed di-agnosis from July 2020 to June 2022.According to the mode of medication,the patients were divided into two groups:the con-trol group(n=39)used valsartan from July 2020 to June 2021,and the observation group(n=39)from July 2021 to June 2022.The number of patients was equal.In combination with indapamide,the clinical efficacy,blood pressure,insulin resist-ance and renal function of the two groups were compared.Results:The total effective rate of the observation group was higher,and the comparison between the two groups was statistically significant(P<o.05).There were no significant differences in blood pressure,insulin resistance and renal function between the two groups before medication(P>0.05).After drug treat-ment,the levels of diastolic blood pressure,systolic blood pressure,insulin resistance,blood creatinine,urea nitrogen and uri-nary microalbumin were lower in the observation group,and the insulin secretion index and insulin sensitivity index were higher in the two groups(P<0.05).Conclusion:Indapamide combined with valsartan in the treatment of hypertension with diabetes can better control blood pressure to reach the standard,reduce insulin resistance,improve renal function,and significantly im-prove the therapeutic effect.